Literature DB >> 22762502

A proposed approach to informed consent for biobanks in China.

Min Liu1, Qingli Hu.   

Abstract

Biobanks are potential goldmines for genomics research. They have become increasingly common as a means to determine the relationship between lifestyle, environmental exposures and predisposition to genetic disease. More and more countries are developing massive national scale biobanks, including Iceland, the UK and Estonia. Now several large-scale regional and national biobanks are planned in China, such as Shanghai Biobank, which is defined as a key-element in Shanghai's twelfth five-year Development Plan of Science and Technology. It is imperative that the authors who are in charge of the ethical aspect of Shanghai Biobank discuss the ethical aspects of these biobanks up front. Currently there is a great deal of heterogeneity in the approaches to informed consent taken by different countries. In the article, after briefly introducing the biobanks in China, we focus on the three most common approaches: classical informed consent, tiered consent, and one-time general (or blanket) consent, and propose a version of the latter for China, based on compelling arguments.
© 2012 John Wiley & Sons Ltd.

Entities:  

Keywords:  biobank; informed consent; one time general consent; opt out

Mesh:

Year:  2012        PMID: 22762502     DOI: 10.1111/j.1467-8519.2012.01985.x

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  2 in total

1.  Following the giant's paces-governance issues and bioethical reflections in China.

Authors:  Zhaochen Wang; Di Zhang; Vincent H Ng; Reidar Lie; Xiaomei Zhai
Journal:  BMC Med Ethics       Date:  2014-10-31       Impact factor: 2.652

Review 2.  ELSI practices in genomic research in East Asia: implications for research collaboration and public participation.

Authors:  Go Yoshizawa; Calvin Wai-Loon Ho; Wei Zhu; Chingli Hu; Yoni Syukriani; Ilhak Lee; Hannah Kim; Daniel Fu Chang Tsai; Jusaku Minari; Kazuto Kato
Journal:  Genome Med       Date:  2014-05-30       Impact factor: 11.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.